ArticleGenes & diseases2023

Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment.

Guodong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.